Juvenile idiopathic arthritis and the gut microbiome: Where are we now?
Publication date: Available online 12 March 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Sanjukta Majumder, Amita Aggarwal (Source: Best Practice and Research Clinical Rheumatology)
Source: Best Practice and Research Clinical Rheumatology - March 12, 2020 Category: Rheumatology Source Type: research

Microbiota-mediated mucosal inflammation in arthritis
Publication date: Available online 6 March 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Meagan E. Chriswell, Kristine A. Kuhn (Source: Best Practice and Research Clinical Rheumatology)
Source: Best Practice and Research Clinical Rheumatology - March 7, 2020 Category: Rheumatology Source Type: research

Scleroderma mimics – Clinical features and management
Publication date: Available online 5 March 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Catherine H. Orteu, Voon H. Ong, Christopher P. Denton (Source: Best Practice and Research Clinical Rheumatology)
Source: Best Practice and Research Clinical Rheumatology - March 7, 2020 Category: Rheumatology Source Type: research

Corrigendum to “Management of fragility fractures in India” [Best Pract Res Clin Rheumatol 33 (2) (2019) 301–309]
Publication date: Available online 25 February 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Nishank Mehta, Bhavuk Garg, Rajesh Malhotra (Source: Best Practice and Research Clinical Rheumatology)
Source: Best Practice and Research Clinical Rheumatology - February 25, 2020 Category: Rheumatology Source Type: research

Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome
Publication date: Available online 15 February 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Lucas L. van den Hoogen, Jacob M. van LaarAbstractTargeted therapies using biological disease-modifying antirheumatic drugs (bDMARDs) and small molecule synthetic drugs have revolutionized rheumatological practice. Initially developed for the treatment of immune arthritis (rheumatoid arthritis, psoriatic arthritis, and spondylarthritis), both bDMARDs and small molecule synthetic drugs are now increasingly entering the space of connective tissue disease (CTD) treatment. Recent clinical trial data in systemic s...
Source: Best Practice and Research Clinical Rheumatology - February 15, 2020 Category: Rheumatology Source Type: research

Pitfalls in the diagnosis of myositis
Publication date: Available online 13 February 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Hector Chinoy, James B. LillekerAbstractThe idiopathic inflammatory myopathies are a group of heterogeneous autoimmune connective tissue diseases. Despite increase in the understanding of these conditions, securing a timely diagnosis and accurate subtype classification remains difficult in some cases. This has important implications for patients, where delayed or inappropriate treatments can have a negative effect on outcomes.Several conditions can mimic myositis, including metabolic myopathies, genetic myopa...
Source: Best Practice and Research Clinical Rheumatology - February 14, 2020 Category: Rheumatology Source Type: research

Inflammatory muscle disease – An update
Publication date: Available online 8 February 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Sara Baig, Julie J. PaikAbstractIdiopathic inflammatory myopathies (IIM) are a heterogeneous group of inflammatory myopathies whose common feature is immune-mediated muscle injury. There are distinct subgroups including dermatomyositis (DM), polymyositis (PM), inclusion body myositis, and immune-mediated necrotizing myopathy. Antisynthetase syndrome is also emerging as a distinct subgroup with its unique muscle histopathological characteristic of perifascicular necrosis. While the newly updated EULAR/ACR Class...
Source: Best Practice and Research Clinical Rheumatology - February 9, 2020 Category: Rheumatology Source Type: research

The microbiome in autoimmune rheumatic disease
Publication date: Available online 7 February 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Maximilian F. KonigAbstractMicrobial contributions to the immunopathogenesis of autoimmune rheumatic diseases have been studied since the advent of germ theory in the 19th century. With the exception of Group A Streptococcus in rheumatic fever, early studies failed to establish causal relationships between specific pathobionts and rheumatic disease. Today, systemic autoimmune diseases are thought to result from a complex interplay of environmental factors, individual genetic risk, and stochastic events. Intera...
Source: Best Practice and Research Clinical Rheumatology - February 8, 2020 Category: Rheumatology Source Type: research

Evaluation and monitoring of established rheumatoid arthritis
Publication date: Available online 7 February 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Isabel CastrejonAbstractEstablished rheumatoid arthritis (RA) is a term used to distinguish patients with longer disease duration versus early RA or undifferentiated arthritis that may progress to RA. Although, there is no uniform definition for early disease, a cut-off of 2 years is used in most clinical trials and observational studies. In the evaluation of established RA, clinicians should incorporate a comprehensive set of measures addressing: (1) disease activity, especially inflammation that may benefit ...
Source: Best Practice and Research Clinical Rheumatology - February 8, 2020 Category: Rheumatology Source Type: research

Connective tissue diseases (excluding SLE)
Publication date: Available online 4 February 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Ariane L. Herrick, Fredrick M. Wigley (Source: Best Practice and Research Clinical Rheumatology)
Source: Best Practice and Research Clinical Rheumatology - February 5, 2020 Category: Rheumatology Source Type: research

The relationships between cancer and autoimmune rheumatic diseases
Publication date: Available online 3 February 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Laura C. Cappelli, Ami A. ShahAbstractLinks between autoimmune rheumatic diseases and cancer continue to be elucidated. In this review, we explore this complex, bidirectional relationship. First, the increased risk of cancer across the breadth of the autoimmune rheumatic diseases is described. The magnitude of risk and types of tumors seen can differ by the type of autoimmune disease, timing of disease course, and even clinical and laboratory features within a particular autoimmune disease, suggesting that tar...
Source: Best Practice and Research Clinical Rheumatology - February 4, 2020 Category: Rheumatology Source Type: research

Established rheumatoid arthritis – Redefining the concept
Publication date: Available online 29 January 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Katerina Chatzidionysiou, George E. FragoulisAbstractDuring the last few years, there has been a shift of focus in rheumatoid arthritis (RA) research towards earlier disease states. The terms early and established RA are inseparable, and having a clear definition of these two terms is crucial in conducting research and trying to understand the immunopathological mechanisms behind these different disease states. Established RA has been connected to chronic inflammation and a high burden of long-standing disease...
Source: Best Practice and Research Clinical Rheumatology - January 30, 2020 Category: Rheumatology Source Type: research

Raynaud's phenomenon
Publication date: Available online 29 January 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Ariane L. Herrick, Fredrick M. WigleyAbstractRaynaud's phenomenon (RP) is common, affecting approximately 5% of the population, and is important to the rheumatologist because it is often the presenting symptom of connective tissue disease, especially of systemic sclerosis (SSc)-spectrum disorders. RP therefore provides a window of opportunity for early diagnosis. When RP is associated with SSc it is particularly challenging to treat.This review begins with a discussion of some of the recent advances in our und...
Source: Best Practice and Research Clinical Rheumatology - January 30, 2020 Category: Rheumatology Source Type: research

Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach
Publication date: Available online 28 January 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Ghaith Noaiseh, Alan N. BaerAbstractSjögren's syndrome is a systemic autoimmune disease defined by its targeted inflammation of the salivary and lacrimal glands, resulting in dry mouth and eyes in the majority and persistent or recurrent salivary gland enlargement in a minority of those affected. Involvement of major organs, an increased risk of lymphoma, and autoantibodies against ubiquitous cellular ribonucleoproteins define some of its systemic features. Those affected have a high symptom burden and the de...
Source: Best Practice and Research Clinical Rheumatology - January 29, 2020 Category: Rheumatology Source Type: research

Established rheumatoid arthritis. The pathogenic aspects
Publication date: Available online 27 January 2020Source: Best Practice & Research Clinical RheumatologyAuthor(s): Serena Bugatti, Emanuele Bozzalla Cassione, Ludovico De Stefano, Antonio ManzoAbstractThe development of rheumatoid arthritis (RA), at least in its autoantibody-positive subset, evolves through a series of events starting well before the appearance of synovitis. The distinction between ‘early’ and ‘established’ RA is, therefore, an evolving concept. In routine practice, however, the management of RA still starts with the occurrence of clinically detectable synovitis. As such, the synovial membrane rema...
Source: Best Practice and Research Clinical Rheumatology - January 28, 2020 Category: Rheumatology Source Type: research